Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A1 | P04798 | 5/20 | 0.77 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.77 |
| ▸ | CYP1B1 | Q16678 | 5/20 | 0.77 |
| ▸ | POLB | P06746 | 1/20 | 0.77 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.73 |
| ▸ | CYP19A1 | P11511 | 5/20 | 0.73 |
| ▸ | MAPT | P10636 | 3/20 | 0.73 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.73 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.73 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.73 |
| ▸ | TP53 | P04637 | 2/20 | 0.73 |
| ▸ | XDH | P47989 | 2/20 | 0.73 |
| ▸ | ATM | Q13315 | 2/20 | 0.73 |
| ▸ | CA12 | O43570 | 2/20 | 0.73 |
| ▸ | CA4 | P22748 | 2/20 | 0.73 |
| ▸ | DPP4 | P27487 | 2/20 | 0.73 |
| ▸ | CA7 | P43166 | 2/20 | 0.73 |
| ▸ | GSK3B | P49841 | 2/20 | 0.73 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.73 |
| ▸ | HPGD | P15428 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7196754 | 0.91 | CYP1A1 (0.78) | CYP1A1CYP1A2CYP1B1POLBCYP3A4 | |
| SCHEMBL31028356 | 0.87 | CYP19A1 (0.87) | CYP1A1CYP1A2CYP1B1POLBCYP3A4 | |
| Homoeriodictyol SCHEMBL30016824 | 0.87 | CYP1A1 (1.00) | CYP1A1CYP1A2CYP1B1POLBCYP3A4 | |
| Homoeriodictyol SCHEMBL2307702 | 0.87 | CYP1A1 (1.00) | CYP1A1CYP1A2CYP1B1POLBCYP3A4 | |
| Homoeriodictyol SCHEMBL39497 | 0.87 | CYP1A1 (1.00) | CYP1A1CYP1A2CYP1B1POLBCYP3A4 | |
| Homoeriodictyol SCHEMBL30383489 | 0.87 | CYP1A1 (1.00) | CYP1A1CYP1A2CYP1B1POLBCYP3A4 | |
| Homoeriodictyol SCHEMBL29411740 | 0.87 | CYP1A1 (1.00) | CYP1A1CYP1A2CYP1B1POLBCYP3A4 | |
| SCHEMBL25221390 | 0.87 | PTPN1 (0.89) | CYP1A1CYP1A2CYP1B1POLBCYP19A1 | |
| Homoeriodictyol SCHEMBL2019518 | 0.86 | CYP1A1 (0.98) | CYP1A1CYP1A2CYP1B1POLBCYP3A4 | |
| Homoeriodictyol SCHEMBL2024548 | 0.86 | CYP1A1 (0.98) | CYP1A1CYP1A2CYP1B1POLBCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4483866-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OR PREVENTION OF CANCER | Makrolife Biotech GmbH (DE) | 2025-01-01 | — | — | EP | claimed |
| EP-4483866-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OR PREVENTION OF CANCER | Makrolife Biotech GmbH (DE) | 2025-01-01 | — | — | EP | disclosed |
| CN-109890378-A | FOXO1 activity-inhibiting composition | 三得利控股株式会社 | 2019-06-14 | — | — | CN | disclosed |
| US-20170071902-A1 | NOX INHIBITOR AND NFkB INHIBITOR CONTAINING METHOXYFLAVONE | SUNTORY HOLDINGS LIMITED (JP) | 2017-03-16 | — | — | US | disclosed |
| WO-2007115181-A9 | COMPOUNDS EXHIBITING EFFLUX INHIBITOR ACTIVITY AND COMPOSITIONS AND USES THEREOF | EASTMAN CHEM CO (US) | 2008-04-03 | — | — | WO | disclosed |
| US-20070254859-A1 | Compounds exhibiting efflux inhibitor activity and composition and uses thereof | EASTMAN CHEMICAL COMPANY | 2007-11-01 | — | — | US | disclosed |
| WO-2007115181-A2 | COMPOUNDS EXHIBITING EFFLUX INHIBITOR ACTIVITY AND COMPOSITIONS AND USES THEREOF | EASTMAN CHEMICAL COMPANY (US) | 2007-10-11 | — | — | WO | disclosed |
| WO-2003057210-A1 | COMPOSITIONS AND METHODS FOR INCREASING CELL PROLIFERATION COMPRISING A FLAVONOID | KIMBERLY-CLARK WORLDWIDE, INC. (US) | 2003-07-17 | — | — | WO | disclosed |
| US-20030125264-A1 | Methods For Treating Wounds | KIMBERLY-CLARK WORLDWIDE, INC. | 2003-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254859-A1 | Compounds exhibiting efflux inhibitor activity and composition and uses thereof | ABCC4, NCOA4, NR4A3 | CYP1A1 215/4885CYP1A2 319/4885CYP1B1 316/4885 |
| US-20170071902-A1 | NOX INHIBITOR AND NFkB INHIBITOR CONTAINING METHOXYFLAVONE | NOX1, NFKBIA, NOX5 | CYP1A1 602/4885CYP1A2 1169/4885CYP1B1 412/4885 |
| US-20030125264-A1 | Methods For Treating Wounds | FGF2, MMP1, FIBP | CYP1A1 1856/4885CYP1A2 1713/4885CYP1B1 1640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.